











































The Clinical Promise of Biomarkers of Synapse Damage or Loss
in Alzheimer’s Disease
Citation for published version:
Colom Cadena, M, Spires-Jones, T, Zetterberg, H, Blennow, K, Caggiano, A, DeKosky, ST, Fillit, H,
Harrison, JE, Schneider, LS, Scheltens, P, de Haan, W, van Dyck, CH, Izzo, NJ, Catalano, SM & Endpoints
Working Group, SH 2020, 'The Clinical Promise of Biomarkers of Synapse Damage or Loss in Alzheimer’s
Disease', Alzheimer's research & therapy. https://doi.org/10.1186/s13195-020-00588-4
Digital Object Identifier (DOI):
10.1186/s13195-020-00588-4
Link:




Alzheimer's research & therapy
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 23. Jul. 2021
Cognition Therapeutics, Inc.  May 2019 
1 
CONFIDENTIAL 
The Clinical Promise of Biomarkers of Synapse Damage or Loss in 
Alzheimer’s Disease 
Martí Colom-Cadena1, Tara Spires-Jones1, Henrik Zetterberg2,3,4,5, Kaj Blennow2,3, Anthony 
Caggiano6, Steven T. DeKosky7, Howard Fillit8, John E. Harrison9, Lon S. Schneider10, Phillip 
Scheltens11, Willem de Haan11,12, Michael Grundman13, Christopher H. van Dyck14, Nicholas J. 
Izzo6, Susan M. Catalano6*, and the Synaptic Health Endpoints Working Group 
 
  Affiliations of the Authors 
1- Centre for Discovery Brain Sciences, UK Dementia Research Institute at The University 
of Edinburgh, Edinburgh, UK 
2- Department of Psychiatry and Neurochemistry, University of Gothenburg, Mölndal, 
Sweden 
3- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden 
4- Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United 
Kingdom 
5- UK Dementia Research Institute at UCL, London, United Kingdom 
6- Cognition Therapeutics. Inc, Pittsburgh, PA, USA 
7- McKnight Brain Institute, University of Florida, Gainesville, FL, USA 
8- Alzheimer’s Drug Discovery Foundation, New York, NY, USA 
9- Metis Cognition Ltd, Kilmington, UK; Alzheimer Center, AUmc, Amsterdam, The 
Netherlands; Institute of Psychiatry, Psychology & Neuroscience, King’s College 
London, UK 
10- Keck School of Medicine of USC, Los Angeles, CA, USA 
11- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, 
Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands 
12- Department of Clinical Neurophysiology and MEG, VU University Medical Center, 
Amsterdam, Netherlands 
13- Global R&D Partners, San Diego, CA, USA 
14- Alzheimer's Disease Research Unit and Departments of Psychiatry, Neurology, and 
Neuroscience, Yale School of Medicine, New Haven, CT, USA 
 
*Corresponding Author: Susan Catalano, Ph.D., Cognition Therapeutics Inc., 2403 Sidney 
Street, Suite 242, Pittsburgh, PA 15203 (scatalano@cogrx.com) 
 
  





Background: Synapse damage and loss are fundamental to the pathophysiology of Alzheimer’s 
disease (AD) and lead to reduced cognitive function. The goal of this review is to address the 
challenges of forging new clinical development approaches for AD therapeutics that can 
demonstrate reduction of synapse damage or loss. 
The key points of this review include the following: 
 Synapse loss is a downstream effect of amyloidosis, tauopathy, inflammation, and other 
mechanisms occurring in AD 
 Synapse loss correlates most strongly with cognitive decline in AD because synaptic 
function underlies cognitive performance 
 Compounds that halt or reduce synapse damage or loss have a strong rationale as treatments 
of AD 
 Biomarkers that measure synapse degeneration or loss in patients will facilitate clinical 
development of such drugs   
 The ability of methods to sensitively measure synapse density in the brain of a living patient 
through synaptic vesicle glycoprotein 2A (SV2A) positron emission tomography (PET) 
imaging, concentrations of synaptic proteins (e.g., neurogranin or synaptotagmin) in the 
cerebrospinal fluid (CSF), or functional imaging techniques such as quantitative 
electroencephalography (qEEG) provides a compelling case to use these types of 
measurements as biomarkers that quantify synapse damage or loss in clinical trials in AD 
Conclusion: A number of emerging biomarkers are able to measure synapse injury and loss in 
the brain, and may correlate with cognitive function in AD. These biomarkers hold promise 
both for use in diagnostics and in the measurement of therapeutic successes. 
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Alzheimer’s disease (AD) and related dementias afflict nearly 44 million people worldwide 
(1). In the United States, nearly 6 million people have AD, a number that is expected to double 
by 2050 (2). Only symptomatic treatments are currently available, and disease modeling 
techniques suggest that the beneficial effects of current treatments may peak by six months 
(3,4). More effective symptomatic treatments or first-of-a-kind disease-modifying therapies 
for AD continue to be a huge unmet medical need; these treatments would significantly impact 
the quality of life annual healthcare expenditure for AD patients, which were estimated to be 
$277B annually in 2018, and up to $1100B annually by 2050 (2). 
Hypotheses regarding etiology of AD and potential targets for pharmacologic intervention 
have evolved over the recent decades of intense industry and academic research. 
Neurotransmitter hypotheses, while giving rise to the first drugs approved for treating AD, 
generated means for symptomatic relief but failed to generate disease-altering treatments (5). 
Amyloid plaque- and tau tangle-related hypotheses, focused on aggregated Aβ peptide and tau 
protein, appeared to offer promising targets for disease-altering therapies, but most clinical 
programs targeting A generation with small molecules and A clearance with antibodies have 
been disappointing (6,7). Treatment with several anti-A antibodies (solanezumab, with a high 
affinity for monomeric A, and aducanumab and BAN2401, which target fibrillar A) was 
associated with a small slowing of cognitive decline in subsets of patients with AD, but those 
targeting fibrils are associated with vasogenic edema and cerebral microhemorrhages, possibly 
limiting their clinical usefulness (7). Understanding the role of soluble Aβ aggregates has led 
to the new hypotheses that these Aβ oligomers may be responsible for the neurotoxic etiology 
of AD, with hopes that therapeutics that reduce their synaptotoxicity may delay or stop the 
progression of AD (8). Monitoring treatment-related reduction of such toxicity may provide 
suitable biomarker endpoints for drug efficacy and are independent of etiology of disease.  
A foundational principle of neuroscience is that synaptic function underlies cognition. There 
is widespread acceptance of the premise that synapse damage or loss is the objective sign of 
neurodegeneration that is most highly correlated with cognitive decline in AD; this is supported 
by clinical, post-mortem, and non-clinical evidence as summarized below. Objective measures 
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of synaptic damage or loss are therefore a special category of biomarkers expected to be most 
closely correlated with cognitive function. 
The goal of this paper is to review the concept of biomarkers of synapse damage as a potential 
approvable endpoint for treatment in AD and other neurological indications, and to review the 
literature in order to assist biopharmaceutical drug developers and regulators in addressing the 
challenges of forging new pathways for the approval of synaptoprotective AD therapeutics. 
Part 1 will review the critical role played by synaptic damage in the pathophysiologic processes 
that underlie AD and their relation to cognitive decline. Part 2 will review currently available 
biomarkers that measure synapse damage or loss in living patients, with a view towards their 
use as surrogate endpoints in clinical trials in AD.   
The Roles of Synaptic Damage and Loss in Cognition 
The idea that changes in synapses mediate information storage dates back to Santiago Ramon 
y Cajal’s anatomical observations of brain structure in the late 1890’s (9), gained popularity in 
the mid-twentieth century with Hebb’s postulate that synapses between neurons will be 
strengthened if they are active at the same time, and that this process contributes to learning 
(10), and was supported experimentally by Kandel’s studies in Aplysia (11). This concept was 
underscored by the discoveries of synaptic long-term potentiation by Bliss and Lomo (12) and 
the hippocampal synaptic plasticity in memory formation by Morris and colleagues (13). In 
recognition of the importance of synaptic function to cognition, awards including the Brain 
Prize and the Nobel Prize have been awarded to multiple scientists for their work in this field. 
Synapse dysfunction and loss correlates most strongly with the pathological cognitive decline 
experienced in Alzheimer’s disease (14–19). This association was initially described through 
two independent methods, the estimation of synapse number using electron microscopy 
techniques (16) and measurements of synaptic protein concentrations (19), each of which 
showed a strong correlation between synapse number (or synaptic proteins) and cognitive 
scores on the Mini-Mental Status Examination (MMSE). This concept has been robustly 
replicated using a variety of approaches (14,18,20–26), including disease models. While the 
molecular cascades leading to synapse degeneration in AD have yet to be fully determined, 
there is ample evidence from both human brain and disease models supporting synaptotoxic 
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roles of soluble pathological forms of Aβ and tau, as well as glial-mediated neuroinflammation 
(see (14) for an excellent recent meta-analysis). This paper will review evidence of these 
mechanisms, as well as approaches for their detection in patients.  
Mechanisms of Synapse Damage and Loss in AD 
Amyloid plaques formed of aggregated Aβ peptide are one of the defining pathological lesions 
of AD (27–29). In both human brain and mouse models expressing familial AD-associated 
amyloid precursor protein and presenilin mutations, plaques are associated with local synapse 
loss [Figure 1, (30–34)] as well as memory and synaptic plasticity deficits (35–37). However, 
total plaque load is not the factor most strongly correlated with cognitive decline (38) or 
synaptic pathology (17,39) in AD. Instead, abundant data demonstrate that soluble forms of 
Aβ, rather than the large insoluble fibrils in plaques, are toxic to synapses (15,40). Lambert 
and colleagues found that fibril-free synthetic forms of Aβ oligomers (AβO) inhibited long-
term potentiation (LTP) ex vivo (41), and in 2002 Walsh and colleagues demonstrated that 
naturally secreted AβO disrupt LTP in vivo (42). Since then many studies have shown that 
AβO may drive the cognitive impairment found in animal models of AD (43–45), and 
potentially also in human AD (46–48).  
Exposure to oligomers in vitro produces rapid reduction in expression of many synaptic 
proteins required for normal neurotransmission and for learning and memory formation within 
hours (49); longer exposure produces frank loss of synapses and spines (45,49–51). Higher, 
non-physiological concentrations result in rapid neuronal cell death.  
The presence of AβO has been correlated with synaptic plasticity impairment and frank 
synapse loss in mice and cell models (45,49–51) and in human brains in AD (30,52,53). 
Furthermore, AβO have been visualized within individual synapses of both mouse models and 
AD cases using high resolution imaging techniques (30,31,54), arguing strongly that they may 
directly contribute to synaptic and cognitive dysfunction. 




Figure 1: High-Resolution Array Tomography Imaging Reveals Plaque-Associated Synapse 
Loss in Human Temporal Cortex. Scale Bar: 10 Micrometers. 
 
While Aβ monomers may interact with many receptors, in model systems AβO have been 
demonstrated to bind to synaptic receptors including cellular prion protein, NgR1, EphB2, and 
PirB/LilrB2; additional receptor proteins have yet to be rigorously defined (55–61). One 
important regulator of the oligomer receptor complex is the sigma-2 protein receptor complex 
(62,63), the target of the AD disease-modifying drug candidate CT1812 (64). Downstream of 
interacting with synaptic receptors, robust evidence suggests AβO cause calcium influx and 
downstream synaptic dysfunction (15,65,66). 
Another defining neuropathological lesion of AD is the aggregation of truncated, misfolded, 
and hyperphosphorylated tau into neurofibrillary tangles (27). Tau pathology correlates with 
neuron loss and cognitive decline in AD (28,67). In accordance with the observation that tau 
causes neuron death, mouse models that express tau mutations that cause frontotemporal 
dementias with tau pathology demonstrate neuron loss (68–71), early synapse loss, and 
disruption of neuronal network function (72–77). As has been observed with Aβ, the forms of 
tau that may be toxic are the soluble, non-fibrillar and highly reactive forms, the oligomers 
(78–80).   
Loss of physiological tau function may contribute to synapse degeneration by impairing axonal 
transport of cargoes needed at synapses, including mitochondria (81,82). Part of the synaptic 
and network dysfunction in tauopathy mice and in AD is likely due to direct effects of tau at 
synapses. Along with the canonical microtubule stabilizing role of tau, this versatile protein 
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has also been shown to play a physiological role in dendrites including postsynaptic densities 
and in presynaptic terminals (83–85). In human AD brain, small aggregates of phospho-tau are 
observed in both presynaptic and postsynaptic regions, and several groups have observed 
phospho-tau in biochemically isolated synaptic fractions (85–87). Importantly, accumulation 
of phospho-tau in synaptic fractions was much higher in people with AD (cases) than in people 
with high pathological burdens who did not exhibit dementia symptoms (48). Together, these 
data strongly indicate that pathological forms of tau at synapses contribute to synaptic 
dysfunction. 
Based on the genetic causes of rare forms of familial AD, which all act to increase Aβ 
accumulation, and the timing of pathological development where plaque pathology is an early 
pathological feature preceding appreciable tau pathology by many years, it is widely thought 
that Aβ is “upstream” of tau in initiating AD pathogenesis (88). One of the key challenges in 
this field is understanding the links between Aβ and tau, and recent data indicate that these 
proteins may cooperate to cause synaptic degeneration. Several pathways involving tau have 
been implicated in AβO-mediated synapse loss. AβO activation of the NMDA receptor has 
been reported to cause excitotoxicity through the recruitment of Fyn kinase by tau to the post-
synaptic density in mice (83,89,90). Lowering tau levels also protects against some of the 
synaptic effects of AβO (91,92). 
Beyond the direct effects of these pathological proteins on neurons and synapses, 
epidemiologic and genetic data strongly implicate inflammatory mechanisms in synapse 
damage in AD. In particular, recent data indicate that microglia may play an active role in 
synapse loss (93). The most important genetic risk factor for late-onset AD is inheritance of 
the apolipoprotein E epsilon 4 (APOE 4) allele (94). The ApoE4 isoform is highly expressed 
in astrocytes under physiological conditions, but its expression is upregulated in microglia in 
mouse models of AD (95). The effects of AβO at synapses are exacerbated by ApoE4 in 
plaque-bearing mouse models and human AD brain, and are ameliorated by removing 
endogenous ApoE (30,96,97). Triggering receptor expressed on myeloid cells 2 (TREM2), 
complement receptor 1 (CR1), and CD33 are all expressed in microglia, where they may affect 
phagocytosis of synapses (93). The complement system has emerged recently as particularly 
interesting in AD because the tagging of synapses with C1q downstream of both Aβ and tau 
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pathology causes CR3 mediated microglial phagocytosis of synapses (98–102). While several 
members of the complement pathway have been observed to be upregulated in AD brain and 
to correlate with tau pathology (101,102), it remains unknown whether microglial phagocytosis 
of synapses in human disease actively drives synapse loss or simply removes synapses after 
damage has occurred.  
Importantly, in mouse models of AD, the effects on synapses of key elements of AD 
pathogenesis—AβO, tau, or inflammation—are reversible. In multiple studies, deficits in LTP, 
memory impairment, and synapse loss recover in mice when levels of AβO, tau, or 
inflammation are lowered (69,103–108). This plasticity of synaptic connections and their 
potential for recovery lends hope for therapeutics that reduce synaptotoxicity in AD. 
Regardless of the causative role of AβO and the contributions to disease progression of tau, 
p-tau, glia, and inflammation processes, synapse dysfunction has a number of downstream 
neurophysiological consequences including altered neuronal oscillatory behavior and an 
imbalance between excitation and inhibition. These alter neural circuit function and adversely 
impact behavior. As such, normal synapse number and function is the basis for cognitive 
performance and is an ideal measure of brain damage due to disease. 
Biomarkers of Synapse Damage or Loss 
The importance of synapses in cognition and the strong links among synapses, AD 
pathophysiology, and the symptoms observed in AD make a compelling case for the use of 
biomarkers of synapse damage or loss as proxies for synaptic and cognitive function in AD. A 
recent publication of the NIA-AA Research Framework emphasized the necessity of a 
biological definition of the disease for clinical progress, and established the A/T/N biomarker 
classification system, where “A” stands for amyloid beta, “T” for tau, and “N” for 
neurodegeneration (109), a broad concept that includes destruction of system-level circuits and 
regional volume loss, as well as injury to individual cellular elements such as axons, dendrites, 
and synapses. The extent to which this A/T/N biomarker classification system is confined to 
studies of the pathobiology of AD, versus used to define patient populations that are enrolled 
into clinical trials, will be subject of valuable scientific discussion (110). In the remainder of 
this paper we will focus on “N” type biomarkers specifically related to synapse damage or loss. 
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Visualization of synapses in the living brain has recently been described through the labelling 
of synaptic vesicle glycoprotein 2A (SV2A) with the [11C]UCB-J positron emission 
tomography (PET) ligand (111–113). (Additional SV2A radioligands, [11C]UCB-A and 
[18F]UCB-H, have also been under development.) Comparing a group of AD cases with 
cognitively healthy aged cases, a reduction of approximately 40% of SV2A signal was 
observed in the hippocampus in AD cases (114). The use of this PET ligand to measure synapse 
loss longitudinally in AD is not yet well established. However, as a direct measure of synapse 
density, this biomarker in combination with other cerebrospinal fluid (CSF) biomarkers and 
functional imaging approaches such as magnetic resonance imaging (MRI), quantitative 
electroencephalogram (qEEG), or fluorine-18 fluorodeoxyglucose PET (FDG-PET), is 
independent of the disease hypothesis and has the potential to be a strong indicator of brain 
degeneration and cognitive status (Figure 2). Recent innovations such as this ability to 
sensitively measure synapse density in the brain of a living patient via SV2A PET imaging, 
low concentrations of synaptic protein proteolytic fragments in the CSF via sensitive ELISAs 
or LC/MSMS methods, changes in cortical synaptic currents measured by qEEG, or disruption 
of glucose metabolism measured by FDG-PET promise to revolutionize the ability to stage 
patients and to define disease more precisely. Furthermore, as synapses are a fundamental brain 
structure responsible for cognitive output, measures of synapse density have the most value in 
their ability to assess responses to disease-modifying treatments. 
Folowing the identification of synaptic protein fragments of neurogranin, SNAP-25, and 
synaptotagmin in CSF (115,116), specific protein biomarkers of synapse degeneration have 
begun to emerge in recent years. Protein fragments of neurogranin, a dendritic protein involved 
in LTP, are increased in CSF of patients with AD, and full-length neurogranin is decreased in 
postmortem brain tissues (117,118). Furthermore, encouraging data show that increased 
neurogranin fragments in CSF correlate with future cognitive decline, brain atrophy, and 
glucose metabolism, even at early stages of the disease (117,119–121), and that the increase in 
CSF neurogranin seems to be specific for AD (122,123). This use of CSF measurement of 
neurogranin concentration underlies the concept that an accurate biomarker of synapse loss 
reflects cognitive function based on the correlation between cognitive function and synaptic 
proteins in post-mortem brain. 
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Other synaptic proteins including SNAP25, RAB3A, GAP43, AMPA receptor subunits, and a 
number of other proteins also show promise as CSF biomarkers of synaptic damage and loss 
(24,25,124,125). In addition, recent research proposes inflammatory markers, detectable in the 
CSF, as possible biomarkers of neurodegeneration in AD, though their correlation to synapse 
loss in particular remains unclear (126). Biomarkers of glial activation such as CSF TREM2, 
chitotriosidase, CCL2, and YLK-40 have been observed in AD CSF (127–130). Eventually, a 
panel of synaptic protein biomarkers may be a reliable readout for the different aspects of 
synapse loss (pre-synaptic, synaptic vesicle, and dendritic) and a predictor of memory decline. 
Indeed, a recent study found that a group of synaptic proteins changes in CSF before markers 
of neurodegeneration are observed in AD (131). Although CSF collection is more invasive 
than blood sampling, robust blood-based biomarkers of synaptic damage are not yet available. 
It is, for example, possible to measure neurogranin concentration in plasma, but there is no 
plasma-CSF correlation (119,132). It may be possible to develop higher sensitivity assays and 
analyses of neuron-derived exosomes in blood with advancing technologies (130,133). 




Figure 2: Amyloid and Tau Biomarkers can be Used to Confirm AD Pathology, and Biomarkers 
of Synaptic Damage and Loss will be Useful for Predicting Cognitive Decline. 
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Finally, functional imaging approaches are additional tools for visualizing the health and 
function of neurons affected by AD. EEG represents a dynamic measurement of synaptic 
function in cortical pyramidal neuronal dendrites that can capture the summed excitatory and 
inhibitory post-synaptic potentials at a macroscopic spatial scale with millisecond time 
resolution (134–137). Overall, quantitative EEG analysis provides the most direct and dynamic 
clinical representation of neuronal and synaptic function in AD patients; however, while it is 
sensitive to changes in neuronal circuit responses resulting from synaptic dysfunction, it cannot 
discriminate between the exact mechanisms of action underlying synaptic dys/function. 
Alterations in quantitative measures derived from EEG data in patients with AD have been 
widely described and have been shown to be sensitive to disease progression (134,138,139) 
and to correlate with CSF biomarkers of AD (140). Furthermore, EEG is non-invasive, robust, 
efficacious, and widely available in hospitals. Although EEG itself is an ‘old’ technique, 
quantitative instead of visual analysis of EEG signals provides a wealth of information and is 
a novel and rapidly developing method in modern neuroscience. Spectral power measures (i.e., 
the percentage of the total brain activity accounted for by a specific wave frequency) in task-
free EEGs can be calculated and reflect the oscillatory activity of the underlying brain network 
responsible for cognitive functioning. In patients with AD, the EEG shows distinct changes in 
spectral power indicating a gradual, diffuse slowing of brain electrical activity with progression 
of the disease (138). In particular, the gradual relative increase of neuronal theta (4-8 Hz) 
activity appears to be a robust sign in early AD. It has been recently demonstrated that theta 
band activity is a marker of future cognitive decline in non-demented amyloid-positive subjects 
with additive value above other markers of disease progression such as medial temporal 
atrophy on MRI (141), and importantly, that its increase can be reversed in response to 
approved AD therapeutics (142–151).  
In addition to EEG, the use of fluorine-18 fluorodeoxyglucose PET (FDG-PET), which enables 
the visualization of glucose metabolism rates in the brain, has been investigated for its use in 
AD. In neurons, the demand for glucose is driven partly by synaptic terminals, which generate 
ATP needed for synthesis, release, and recycling of neurotransmitter molecules, for the 
maintenance of the normal resting potential, and for the recovery from action potentials. The 
cerebral metabolic rate of glucose as measured with FDG-PET provides a direct index of 
synaptic functioning and an indirect measure of synaptic density (152). Therefore, a disruption 
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in glucose metabolism may be a very direct determinant of synaptic dysfunction [reviewed in 
(153)]. The ability to detect changes in glucose metabolism prior to the onset of clinical 
symptoms of AD may aid earlier diagnosis of AD (153). Data from the Alzheimer's Disease 
Neuroimaging Initiative (ADNI) have confirmed longitudinal associations between FDG-PET 
and clinical measures (154) and have suggested that FDG-PET may help to increase the 
statistical power of diagnosis over conventional cognitive measures, aid subject selection, and 
substantially reduce the sample size required for clinical trials (155,156), though these findings 
must be confirmed in broader sample sizes and longer studies, and require further clarification 
regarding their applicability to AD or other types of dementias. Therapeutic trials have 
provided strong support for the use of FDG-PET as a clinically relevant primary biomarker 
outcome in proof of concept studies, that has the power to detect active-placebo differences 
less than half as great as the best clinical measures (157). However, additional studies showing 
a relationship between an effective treatment’s FDG-PET and clinical findings are needed to 
provide further support for its “theragnostic” value. 
A key further issue for future exploration is the longitudinal relationship between biomarkers 
and cognitive outcome measures. Even modest correlations between the two would yield 
helpful evidence of clinical relevance. Recent studies have observed modest correlations 
between the International Shopping List Test, a measure of episodic memory, with various 
volumetric MRI measures and especially hippocampal volume (158). Change over time 
correlations would provide further helpful support. Furthermore, as understanding of these 
biomarkers improves, their use may help in discerning AD from other types of dementias, in 
particular through localization of compromised synapses to the frontal lobe, temporal lobe, and 
other brain regions. Finally, opportunities for biomarker validation are offered by the extension 
of assessment to domains of cognition known to be compromised early in the disease process. 
Recent FDA draft guidance has called for trials to feature the use of ‘sensitive 
neuropsychological measures.’ Commentators on the draft guidance have highlighted the need 
for trials to include measures of spatial memory skills, working memory, attention, and 
executive function (159). 
 
  




Synapses are essential parts of neurons that form the requisite connections of the neuronal 
networks that underlie cognition. The cognitive impairment in AD closely parallels the loss of 
synapses due to the toxic effects of Aβ, tau, and inflammation. Emerging biomarkers of 
synapse damage reflect such synapse injury and loss in the brain due to disease. Hence, 
biomarkers of synapse damage and loss, especially the use of multiple categories of biomarkers 
in combination with one another, hold great promise as biological measures that should 
correlate with cognitive function in AD. 
 
List of Abbreviations 
 AβO (Aβ oligomers) 
 AD (Alzheimer’s disease) 
 APOE 4 (apolipoprotein E epsilon 4) 
 CSF (cerebrospinal fluid) 
 EEG (electroencephalography) 
 FDA (US Food and Drug Administration 
 FDG-PET (fluorine-18 fluorodeoxyglucose PET) 
 LTP (long-term potentiation) 
 MRI (magnetic resonance imaging) 
 MMSE (Mini-Mental Status Examination) 
 SV2A PET (synaptic vesicle glycoprotein 2A positron emission tomography) 








Ethics approval and consent to participate: 
Figure 1 was produced using human tissue obtained from the Edinburgh MRC Sudden death 
Brain Bank. Use of human tissue for post-mortem studies has been reviewed and approved by 
the Edinburgh Brain Bank ethics committee and the ACCORD medical research ethics 
committee (approval number 15-HV-016; ACCORD is the Academic and Clinical Central 
Office for Research and Development, a joint office of the University of Edinburgh and NHS 
Lothian). The Edinburgh Brain Bank is a Medical Research Council funded facility with 
research ethics committee (REC) approval (11/ES/0022).  
Consent for publication: 
Not applicable 
Availability of data and materials: 
The datasets used and/or analyzed during the current study are available from the 
corresponding author on reasonable request 
Competing interests: 
Anthony Caggiano, Nicholas Izzo, and Susan Catalano are employees or have financial 
interest in Cognition Therapeutics, Inc. Henrik Zetterberg has served at scientific advisory 
boards for Cognition Therapeutics, Roche Diagnostics, Wave and Samumed, has given 
lectures in symposia sponsored by Biogen and Alzecure, and is a co-founder of Brain 
Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the 
University of Gothenburg. Tara Spires-Jones is a scientific advisory board member of 
Cognition Therapeutics and receives collaborative grant funding from two pharmaceutical 
companies. John Harrison has received consultancy payments and honoraria from the 
following organizations in the past 2 years: 23andMe, Alzecure, Aptinyx, Athira Pharma, 
Axon Neuroscience, Axovant, Biogen, Boehringer Ingelheim, CRF Bracket, Cognition 
Therapeutics, Compass Therapeutics, Curasen, DeNDRoN, EIP Pharma, Eisai, Eli Lilly, 
GfHEu, Heptares, Johnson & Johnson, Lundbeck, Lysosome Therapeutics, Merck, 
Neurodyn, Neurotrack, Novartis, Nutricia, Probiodrug, Regeneron, Rodin Therapeutics, 
Roivant, Sanofi, Takeda, vTv Therapeutics and Winterlight Labs. Kaj Blennow has served 
as a consultant or at advisory boards for Alector, Biogen, Cognition Therapeutics, Lilly, 
Cognition Therapeutics, Inc.  May 2019 
16 
CONFIDENTIAL 
MagQu, Novartis and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions 
in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg. 
Christopher van Dyck has served as a consultant or scientific advisor in the past 2 years for 
Roche, Eisai, and Kyowa Kirin and received grant support for clinical trials from Roche, 
Genentech, Eisai, Biogen, Eli Lilly, Novartis, Merck, Biohaven, and Janssen. Lon Schneider 
reports grants and personal fees from Eli Lilly, personal fees from Avraham, Ltd, personal 
fees from Boehringer Ingelheim, grants and personal fees from Merck, personal fees from 
Neurim, Ltd, personal fees from Neuronix, Ltd, personal fees from Cognition Therapeutics, 
personal fees from Eisai, personal fees from Takeda, personal fees from vTv, grants and 
personal fees from Roche/Genentech, grants from Biogen, grants from Novartis, personal 
fees from Abbott, grants from Biohaven, outside the submitted work. Philip Scheltens 
reports consultancies with Axon Neuroscience, Cognition Therapeutics, Vivoryon, and 
Novartis, as well as a DSMB membership with Genentech. Michael Grundman is a paid 
consultant to Cognition Therapeutics. Howard Fillit has been a consultant to Axovant, vTv, 
Lundbeck, Otsuka, Lilly, Biogen (RTI), Roche, Genentech, Merck, Samus, Pfizer, and 
Alector in the past five years, and has no conflicts that are related to this manuscript. Steven 
T. DeKosky is a member of the Neuroscience Advisory Board for Amgen, Chair of the 
Medical Scientific Advisory Board for Acumen, Chair of the Drug Monitoring Committee 
for Biogen, Chair of the Medical Advisory Board for Cognition Therapeutics, and Editor for 
Dementia for UpToDate. Martí Colom Cadena and Willem de haan have no conflicts of 




All authors contributed equally to the preparation and review of this document 
Acknowledgements: 
  




1.  Nichols E, Szoeke CEI, Vollset SE, Abbasi N, Abd-Allah F, Abdela J, et al. Global, 
regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a 
systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 
2019;18(1):88–106.  
2.  Association A. 2018 Alzheimer’s disease facts and figures. Alzheimer’s Dement 
[Internet]. Elsevier; 2018 Mar 1 [cited 2018 Jun 18];14(3):367–429. Available from: 
https://www.sciencedirect.com/science/article/pii/S1552526018300414 
3.  Persson CM, Wallin AK, Levander S, Minthon L. Changes in cognitive domains during 
three years in patients with Alzheimer’s disease treated with donepezil. BMC Neurol 
[Internet]. 2009 Feb 10;9:7. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/19208247 
4.  Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T, et al. Disease 
progression meta-analysis model in Alzheimer’s disease. Alzheimers Dement [Internet]. 
2010 Jan;6(1):39–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19592311 
5.  Kandimalla R, Reddy PH. Therapeutics of Neurotransmitters in Alzheimer’s Disease. J 
Alzheimers Dis [Internet]. 2017;57(4):1049–69. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/28211810 
6.  Knopman DS. Lowering of Amyloid-Beta by β-Secretase Inhibitors - Some Informative 
Failures. N Engl J Med [Internet]. 2019;380(15):1476–8. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/30970194 
7.  van Dyck CH. Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls 
and Promise. Biol Psychiatry [Internet]. Elsevier Inc; 2018;83(4):311–9. Available from: 
https://doi.org/10.1016/j.biopsych.2017.08.010 
8.  Viola KL, Klein WL. Amyloid beta oligomers in Alzheimer’s disease pathogenesis, 
treatment, and diagnosis. Acta Neuropathol. 2015;129:183–206.  
9.  y Cajal SR. Histology of the nervous system of man and vertebrates, Volume 1. New 
York, NY: Oxford University Press; 1995.  
Cognition Therapeutics, Inc.  May 2019 
18 
CONFIDENTIAL 
10.  Hebb D. The Organization of Behavior: A Neuropsychological Theory [Internet]. New 
York, NY: Wiley; 1949. Available from: http://doi.wiley.com/10.1002/sce.37303405110 
11.  Kandel ER. The molecular biology of memory storage: a dialogue between genes and 
synapses. Science [Internet]. 2001 Nov 2;294(5544):1030–8. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/11691980 
12.  Bliss T V, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area 
of the anaesthetized rabbit following stimulation of the perforant path. J Physiol [Internet]. 
1973 Jul;232(2):331–56. Available from: http://www.ncbi.nlm.nih.gov/pubmed/4727084 
13.  Takeuchi T, Duszkiewicz AJ, Morris RGM. The synaptic plasticity and memory 
hypothesis: encoding, storage and persistence. Philos Trans R Soc Lond B Biol Sci 
[Internet]. 2014 Jan 5;369(1633):20130288. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/24298167 
14.  De Wilde MC, Overk CR, Sijben JW, Masliah E. Meta-analysis of synaptic pathology in 
Alzheimer’s disease reveals selective molecular vesicular machinery vulnerability. 
Alzheimer’s Dement [Internet]. Elsevier Inc.; 2016;12(6):633–44. Available from: 
http://dx.doi.org/10.1016/j.jalz.2015.12.005 
15.  Spires-Jones TL, Hyman B. The Intersection of Amyloid Beta and Tau at Synapses in 
Alzheimer’s Disease. Neuron [Internet]. Elsevier Inc.; 2014;82(4):756–71. Available 
from: http://dx.doi.org/10.1016/j.neuron.2014.05.004 
16.  DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer’s disease: 
correlation with cognitive severity. Ann Neurol [Internet]. 1990 May;27(5):457–64. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/2360787 
17.  Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P. Synaptic pathology in 
Alzheimer’s disease: relation to severity of dementia, but not to senile plaques, 
neurofibrillary tangles, or the ApoE4 allele. J Neural Transm [Internet]. 1996;103(5):603–
18. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8811505 
18.  DeKosky ST, Scheff SW, Styren SD. Structural correlates of cognition in dementia: 
quantification and assessment of synapse change. Neurodegeneration [Internet]. 1996 
Dec;5(4):417–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9117556 
Cognition Therapeutics, Inc.  May 2019 
19 
CONFIDENTIAL 
19.  Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of 
cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of 
cognitive impairment. Ann Neurol [Internet]. 1991 Oct;30(4):572–80. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/1789684 
20.  Scheff SW, Price DA. Synaptic pathology in Alzheimer’s disease: a review of 
ultrastructural studies. Neurobiol Aging [Internet]. 2003 Dec [cited 2014 May 
13];24(8):1029–46. Available from: 
http://linkinghub.elsevier.com/retrieve/pii/S0197458003001805 
21.  Scheff SW, Price DA, Ansari MA, Roberts KN, Schmitt FA, Ikonomovic MD, et al. 
Synaptic change in the posterior cingulate gyrus in the progression of Alzheimer’s 
disease. J Alzheimers Dis [Internet]. 2015 Apr 15;43(3):1073–90. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/24529280 
22.  Scheff SW, Price DA, Schmitt FA, Roberts KN, Ikonomovic MD, Mufson EJ. Synapse 
stability in the precuneus early in the progression of Alzheimer’s disease. J Alzheimers 
Dis [Internet]. 2013;35(3):599–609. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/23478309 
23.  Kashani A, Lepicard E, Poirel O, Videau C, David JP, Fallet-Bianco C, et al. Loss of 
VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive decline in 
Alzheimer disease. Neurobiol Aging [Internet]. 2008 Nov;29(11):1619–30. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/17531353 
24.  Bereczki E, Branca RM, Francis PT, Pereira JB, Baek J-H, Hortobágyi T, et al. Synaptic 
markers of cognitive decline in neurodegenerative diseases: a proteomic approach. Brain 
[Internet]. 2018;141(2):582–95. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/29324989 
25.  Bereczki E, Francis PT, Howlett D, Pereira JB, Höglund K, Bogstedt A, et al. Synaptic 
proteins predict cognitive decline in Alzheimer’s disease and Lewy body dementia. 
Alzheimers Dement [Internet]. 2016;12(11):1149–58. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/27224930 
26.  Whitfield DR, Vallortigara J, Alghamdi A, Howlett D, Hortobágyi T, Johnson M, et al. 
Cognition Therapeutics, Inc.  May 2019 
20 
CONFIDENTIAL 
Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer’s 
disease: association with cognitive impairment. Neurobiol Aging [Internet]. 2014 
Dec;35(12):2836–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25104558 
27.  Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, et al. 
Alzheimer’s disease. Lancet (London, England) [Internet]. 2016 Jul 30;388(10043):505–
17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26921134 
28.  Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in 
Alzheimer disease. Cold Spring Harb Perspect Med [Internet]. 2011 Sep;1(1):a006189. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/22229116 
29.  Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National 
Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment 
of Alzheimer’s disease. Alzheimers Dement [Internet]. 2012 Jan;8(1):1–13. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/22265587 
30.  Koffie RM, Hashimoto T, Tai H-C, Kay KR, Serrano-Pozo A, Joyner D, et al. 
Apolipoprotein E4 effects in Alzheimer’s disease are mediated by synaptotoxic oligomeric 




31.  Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza 
M, et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates 
with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A [Internet]. 
2009/02/21. 2009 Mar 10;106(10):4012–7. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2656196&tool=pmcentrez&re
ndertype=abstract 
32.  Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, et al. 
Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated 
by gene transfer and intravital multiphoton microscopy. J Neurosci [Internet]. 2005 Aug 
3;25(31):7278–87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16079410 
Cognition Therapeutics, Inc.  May 2019 
21 
CONFIDENTIAL 
33.  Jackson RJ, Rudinskiy N, Herrmann AG, Croft S, Kim JM, Petrova V, et al. Human tau 
increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse 
model of Alzheimer’s disease. Eur J Neurosci [Internet]. 2016;44:3056–66. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/27748574 
34.  Yu Y, Jans DC, Winblad B, Tjernberg LO, Schedin-Weiss S. Neuronal Aβ42 is enriched 
in small vesicles at the presynaptic side of synapses. Life Sci Alliance [Internet]. 2018 Jun 
14;1(3):e201800028. Available from: http://www.life-science-
alliance.org/lookup/doi/10.26508/lsa.201800028 
35.  Ashe KH, Zahs KR. Probing the biology of Alzheimer’s disease in mice. Neuron 
[Internet]. 2010 Jun 10;66(5):631–45. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/20547123 
36.  Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, et al. APP mouse 
models for Alzheimer’s disease preclinical studies. EMBO J [Internet]. 
2017;36(17):2473–87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28768718 
37.  Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, et al. Single App knock-in 
mouse models of Alzheimer’s disease. Nat Neurosci [Internet]. 2014;17(5):661–3. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/24728269 
38.  Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of 
Alzheimer disease neuropathologic changes with cognitive status: a review of the 
literature. J Neuropathol Exp Neurol [Internet]. 2012 May;71(5):362–81. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/22487856 
39.  Masliah E, Hansen L, Albright T, Mallory M, Terry RD. Immunoelectron microscopic 
study of synaptic pathology in Alzheimer’s disease. Acta Neuropathol [Internet]. 
1991;81(4):428–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1903014 
40.  Cline EN, Bicca MA, Viola KL, Klein WL. The Amyloid-β Oligomer Hypothesis: 
Beginning of the Third Decade. J Alzheimers Dis [Internet]. 2018;64. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/29843241 
41.  Lambert MP, Barlow  a K, Chromy B a, Edwards C, Freed R, Liosatos M, et al. 
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system 
Cognition Therapeutics, Inc.  May 2019 
22 
CONFIDENTIAL 




42.  Walsh DM, Klyubin I, Fadeeva J V., Cullen WK, Anwyl R, Wolfe MS, et al. Naturally 
secreted oligomers of amyloid β protein potently inhibit hippocampal long-term 
potentiation in vivo. Nature [Internet]. Nature Publishing Group; 2002 Apr 4 [cited 2018 
Jul 9];416(6880):535–9. Available from: http://www.nature.com/articles/416535a 
43.  Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski M a, Selkoe DJ, et al. 
Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat 
Neurosci [Internet]. 2005 Jan [cited 2014 May 2];8(1):79–84. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/15608634 
44.  Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-
beta protein assembly in the brain impairs memory. Nature [Internet]. 2006 Mar 16 [cited 
2014 Apr 29];440(7082):352–7. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/16541076 
45.  Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-
beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity 




46.  Lesné SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, et al. Brain 
amyloid-β oligomers in ageing and Alzheimer’s disease. Brain [Internet]. 2013 
May;136(Pt 5):1383–98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23576130 
47.  Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, et al. Amyloid-β 
oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol 
[Internet]. 2013 Jan [cited 2014 Apr 28];73(1):104–19. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3563737&tool=pmcentrez&re




48.  Perez-Nievas BG, Stein TD, Tai H-C, Dols-Icardo O, Scotton TC, Barroeta-Espar I, et al. 
Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology. Brain 
[Internet]. 2013 Aug;136(8):2510–26. Available from: 
https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/awt171 
49.  Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, et al. Abeta 
oligomer-induced aberrations in synapse composition, shape, and density provide a 
molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci [Internet]. 
2007 Jan 24 [cited 2014 May 2];27(4):796–807. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/17251419 
50.  Wang Z, Jackson RJ, Hong W, Taylor WM, Corbett GT, Moreno A, et al. Human Brain-
Derived Aβ Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That 
Requires APP. J Neurosci [Internet]. 2017 Dec 6;37(49):11947–66. Available from: 
http://www.biorxiv.org/content/early/2017/05/09/135673 
51.  Calabrese B, Shaked GM, Tabarean I V, Braga J, Koo EH, Halpain S. Rapid, concurrent 
alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta 




52.  Lue L-F, Kuo Y-M, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble Amyloid β 
Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease. Am J 
Pathol [Internet]. 1999 Sep;155(3):853–62. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/S000294401065184X 
53.  Bao F, Wicklund L, Lacor PN, Klein WL, Nordberg A, Marutle A. Different β-amyloid 
oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired 
cholinergic activity. Neurobiol Aging [Internet]. Elsevier Inc.; 2012 Apr [cited 2014 May 
15];33(4):825.e1-13. Available from: 
http://dx.doi.org/10.1016/j.neurobiolaging.2011.05.003 
Cognition Therapeutics, Inc.  May 2019 
24 
CONFIDENTIAL 
54.  Pickett EK, Koffie RM, Wegmann S, Henstridge CM, Herrmann AG, Colom-Cadena M, 
et al. Non-Fibrillar Oligomeric Amyloid-β within Synapses. J Alzheimer’s Dis. 
2016;53(3):787–800.  
55.  Benilova I, De Strooper B. Neuroscience. Promiscuous Alzheimer’s amyloid: yet another 
partner. Science [Internet]. 2013 Sep 20 [cited 2014 May 21];341(6152):1354–5. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/24052299 
56.  Haas LT, Salazar S V, Kostylev MA, Um JW, Kaufman AC, Strittmatter SM. 
Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling 
in Alzheimer’s disease. Brain [Internet]. 2016 Feb [cited 2018 Oct 18];139(Pt 2):526–46. 
Available from: https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/awv356 
57.  Alon A, Schmidt HR, Wood MD, Sahn JJ, Martin SF, Kruse AC. Identification of the 
gene that codes for the σ 2 receptor. Proc Natl Acad Sci [Internet]. 2017 Jul 
3;114(27):7160–5. Available from: 
http://www.pnas.org/lookup/doi/10.1073/pnas.1705154114 
58.  Xu J, Zeng C, Chu W, Pan F, Rothfuss JM, Zhang F, et al. Identification of the PGRMC1 
protein complex as the putative sigma-2 receptor binding site. Nat Commun [Internet]. 
Nature Publishing Group; 2011 Jul 5 [cited 2014 May 12];2(2):380. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3624020&tool=pmcentrez&re
ndertype=abstract 
59.  Riad A, Zeng C, Weng C-C, Winters H, Xu K, Makvandi M, et al. Sigma-2 
Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL 
Receptor through the Formation of a Ternary Complex. Sci Rep [Internet]. 2018 Nov 
15;8(1):16845. Available from: http://www.nature.com/articles/s41598-018-35430-3 
60.  Smith LM, Strittmatter SM. Binding Sites for Amyloid-β Oligomers and Synaptic 
Toxicity. Cold Spring Harb Perspect Med [Internet]. 2017 May 1;7(5):a024075. Available 
from: http://perspectivesinmedicine.cshlp.org/lookup/doi/10.1101/cshperspect.a024075 
61.  Cissé M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, et al. Reversing EphB2 
depletion rescues cognitive functions in Alzheimer model. Nature [Internet]. 2011 Jan 6 
[cited 2014 May 1];469(7328):47–52. Available from: 





62.  Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, et al. Alzheimer’s therapeutics 
targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal 
receptors is displaced by drug candidates that improve cognitive deficits. Wu Z-Y, editor. 
PLoS One [Internet]. Public Library of Science; 2014 Jan [cited 2014 Nov 
17];9(11):e111898. Available from: http://dx.plos.org/10.1371/journal.pone.0111898 
63.  Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, et al. Alzheimer’s therapeutics 
targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 
oligomer binding and synaptotoxicity. PLoS One [Internet]. 2014;9(11):e111899. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/25390692 
64.  Grundman M, Morgan R, Lickliter JD, Schneider LS, DeKosky S, Izzo NJ, et al. A phase 
1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel 
therapeutic candidate for Alzheimer’s disease. Alzheimer’s Dement (New York, N Y) 
[Internet]. Elsevier Inc.; 2019;5:20–6. Available from: 
https://doi.org/10.1016/j.trci.2018.11.001 
65.  Kuchibhotla K V, Lattarulo CR, Hyman BT, Bacskai BJ. Synchronous hyperactivity and 
intercellular calcium waves in astrocytes in Alzheimer mice. Science [Internet]. 2009 Feb 
27;323(5918):1211–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19251629 
66.  Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold K-H, Haass C, et al. 
Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer’s 
disease. Science [Internet]. 2008 Sep 19;321(5896):1686–9. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/18802001 
67.  Gomez-Isla T. Neuronal Loss Correlates with but Exceeds Neurofibrillary Tangles in 
Alzheimer’s Disease. Ann Neurol. 1997;41(1):17–24.  
68.  Spires TL, Orne JD, SantaCruz K, Pitstick R, Carlson GA, Ashe KH, et al. Region-
specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of 
tauopathy. Am J Pathol. 2006;168(5):1598–607.  
69.  SantaCruz K. Tau Suppression in a Neurodegenerative Mouse Model Improves Memory 
Cognition Therapeutics, Inc.  May 2019 
26 
CONFIDENTIAL 
Function. Science (80- ) [Internet]. 2005 Jul 15;309(5733):476–81. Available from: 
http://www.sciencemag.org/cgi/doi/10.1126/science.1113694 
70.  Polydoro M, Acker CM, Duff K, Castillo PE, Davies P. Age-Dependent Impairment of 
Cognitive and Synaptic Function in the htau Mouse Model of Tau Pathology. J Neurosci 
[Internet]. 2009 Aug 26;29(34):10741–9. Available from: 
http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.1065-09.2009 
71.  Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, et al. Abundant tau filaments 
and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau 
protein. J Neurosci [Internet]. 2002 Nov 1;22(21):9340–51. Available from: 
isi:000175724500174 
72.  Busche MA. In Vivo Two-Photon Calcium Imaging of Hippocampal Neurons in 
Alzheimer Mouse Models. Methods Mol Biol [Internet]. 2018;1750:341–51. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/29512084 
73.  Fu H, Possenti A, Freer R, Nakano Y, Villegas NCH, Tang M, et al. A tau homeostasis 
signature is linked with the cellular and regional vulnerability of excitatory neurons to tau 
pathology. Nat Neurosci [Internet]. Springer US; 2019;22(1):47–56. Available from: 
http://dx.doi.org/10.1038/s41593-018-0298-7 
74.  Menkes-Caspi N, Yamin HG, Kellner V, Spires-Jones TL, Cohen D, Stern EA. 
Pathological tau disrupts ongoing network activity. Neuron [Internet]. Elsevier Inc.; 
2015;85(5):959–66. Available from: http://dx.doi.org/10.1016/j.neuron.2015.01.025 
75.  Crimins JL, Rocher AB, Peters A, Shultz P, Lewis J, Luebke JI. Homeostatic responses by 
surviving cortical pyramidal cells in neurodegenerative tauopathy. Acta Neuropathol. 
2011;122(5):551–64.  
76.  Rocher AB, Crimins JL, Amatrudo JM, Kinson MS, Todd-Brown MA, Lewis J, et al. 
Structural and functional changes in tau mutant mice neurons are not linked to the 
presence of NFTs. Exp Neurol [Internet]. 2010 Jun;223(2):385–93. Available from: 
https://linkinghub.elsevier.com/retrieve/pii/S0014488609003100 
77.  Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TCC, et al. Synapse Loss 
and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model. Neuron. 




78.  Sealey MA, Vourkou E, Cowan CM, Bossing T, Quraishe S, Grammenoudi S, et al. 
Distinct phenotypes of three-repeat and four-repeat human tau in a transgenic model of 
tauopathy. Neurobiol Dis. 2017;105:74–83.  
79.  Ghag G, Bhatt N, Cantu D V., Guerrero-Munoz MJ, Ellsworth A, Sengupta U, et al. 
Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and 
cross-seeding behavior. Protein Sci. 2018;27(11):1901–9.  
80.  Kopeikina KJ, Hyman BT, Spires-Jones TL. Soluble forms of tau are toxic in Alzheimer’s 
disease. Transl Neurosci [Internet]. 2012 Sep;3(3):223–33. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/23029602 
81.  Kopeikina KJ, Carlson GA, Pitstick R, Ludvigson AE, Peters A, Luebke JI, et al. Tau 
accumulation causes mitochondrial distribution deficits in neurons in a mouse model of 
tauopathy and in human Alzheimer’s disease brain. Am J Pathol [Internet]. Elsevier Inc.; 
2011;179(4):2071–82. Available from: http://dx.doi.org/10.1016/j.ajpath.2011.07.004 
82.  Pickett EK, Rose J, McCrory C, McKenzie CA, King D, Smith C, et al. Region-specific 
depletion of synaptic mitochondria in the brains of patients with Alzheimer’s disease. 
Acta Neuropathol [Internet]. Springer Berlin Heidelberg; 2018;136(5):747–57. Available 
from: https://doi.org/10.1007/s00401-018-1903-2 
83.  Ittner A, Ittner LM. Dendritic Tau in Alzheimer’s Disease. Neuron [Internet]. Elsevier 
Inc.; 2018;99(1):13–27. Available from: https://doi.org/10.1016/j.neuron.2018.06.003 
84.  McInnes J, Wierda K, Snellinx A, Bounti L, Wang YC, Stancu IC, et al. Synaptogyrin-3 
Mediates Presynaptic Dysfunction Induced by Tau. Neuron. 2018;97(4):823–835.e8.  
85.  Zhou L, McInnes J, Wierda K, Holt M, Herrmann AG, Jackson RJ, et al. Tau association 
with synaptic vesicles causes presynaptic dysfunction. Nat Commun [Internet]. Nature 
Publishing Group; 2017;8(May):15295. Available from: 
http://www.nature.com/doifinder/10.1038/ncomms15295 
86.  Tai H, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT. The 
synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is 
associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol [Internet]. 
Cognition Therapeutics, Inc.  May 2019 
28 
CONFIDENTIAL 
Elsevier Inc.; 2012 Oct [cited 2014 May 20];181(4):1426–35. Available from: 
http://dx.doi.org/10.1016/j.ajpath.2012.06.033 
87.  Tai HC, Wang BY, Serrano-Pozo A, Frosch MP, Spires-Jones TL, Hyman BT. Frequent 
and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic 
terminals in Alzheimer’s disease. Acta Neuropathol Commun. 2014;2(1):1–14.  
88.  Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO 
Mol Med [Internet]. 2016;1–14. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/27025652 
89.  Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Dendritic function of 
tau mediates amyloid-β toxicity in alzheimer’s disease mouse models. Cell. 
2010;142(3):387–97.  
90.  Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, et al. Amyloid- /Fyn-Induced 
Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse 
Models of Alzheimer’s Disease. J Neurosci [Internet]. 2011 Jan 12;31(2):700–11. 
Available from: http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.4152-10.2011 
91.  Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing 
Endogenous Tau Ameliorates Amyloid -Induced Deficits in an Alzheimer’s Disease 
Mouse Model. Science (80- ) [Internet]. 2007 May 4;316(5825):750–4. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/17478722 
92.  Shipton OA, Leitz JR, Dworzak J, Acton CEJ, Tunbridge EM, Denk F, et al. Tau protein 
is required for amyloid {beta}-induced impairment of hippocampal long-term 
potentiation. J Neurosci [Internet]. 2011 Feb 2;31(5):1688–92. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/21289177 
93.  Henstridge CM, Hyman BT, Spires-Jones TL. Beyond the neuron–cellular interactions 
early in Alzheimer disease pathogenesis. Nat Rev Neurosci [Internet]. 2019;20(2):1. 
Available from: http://www.nature.com/articles/s41583-018-0113-1 
94.  Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. 
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late 
onset families. Science [Internet]. 1993 Aug 13;261(5123):921–3. Available from: 




95.  Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland 
TK, et al. A Unique Microglia Type Associated with Restricting Development of 
Alzheimer’s Disease. Cell [Internet]. 2017 Jun 15;169(7):1276–1290.e17. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/28602351 
96.  Hudry E, Dashkoff J, Roe AD, Takeda S, Koffie RM, Hashimoto T, et al. Gene transfer of 
human Apoe isoforms results in differential modulation of amyloid deposition and 
neurotoxicity in mouse brain. Sci Transl Med [Internet]. 2013 Nov 20;5(212):212ra161. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/24259049 
97.  Hudry E, Klickstein J, Cannavo C, Jackson R, Muzikansky A, Gandhi S, et al. Opposing 
Roles of apolipoprotein E in aging and neurodegeneration. Life Sci Alliance [Internet]. 
2019;2(1):e201900325. Available from: http://www.life-science-
alliance.org/lookup/doi/10.26508/lsa.201900325 
98.  Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al. 
Complement and microglia mediate early synapse loss in Alzheimer mouse models. 
Science (80- ) [Internet]. 2016;8373(6286):1–9. Available from: 
http://www.sciencemag.org/cgi/doi/10.1126/science.aad8373 
99.  Shi Q, Chowdhury S, Ma R, Le KX, Hong S, Caldarone BJ, et al. Complement C3 
deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Sci 
Transl Med [Internet]. 2017;9(392). Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/28566429 
100.  Davies C, Spires-Jones TL. Complementing Tau: New Data Show that the Complement 
System Is Involved in Degeneration in Tauopathies. Neuron [Internet]. 2018;100(6):1267–
9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30571935 
101.  Litvinchuk A, Wan Y-W, Swartzlander DB, Chen F, Cole A, Propson NE, et al. 
Complement C3aR Inactivation Attenuates Tau Pathology and Reverses an Immune 
Network Deregulated in Tauopathy Models and Alzheimer’s Disease. Neuron [Internet]. 
2018;100(6):1337–1353.e5. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/30415998 
Cognition Therapeutics, Inc.  May 2019 
30 
CONFIDENTIAL 
102.  Dejanovic B, Huntley MA, De Mazière A, Meilandt WJ, Wu T, Srinivasan K, et al. 
Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss 
by C1q Antibodies. Neuron [Internet]. 2018;100(6):1322–1336.e7. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/30392797 
103.  Spires-Jones TL, Mielke ML, Rozkalne A, Meyer-Luehmann M, de Calignon A, Bacskai 
BJ, et al. Passive immunotherapy rapidly increases structural plasticity in a mouse model 
of Alzheimer disease. Neurobiol Dis [Internet]. 2009 Feb [cited 2014 May 21];33(2):213–
20. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2672591&tool=pmcentrez&re
ndertype=abstract 
104.  Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, et al. 
Reversibility of Tau-related cognitive defects in a regulatable FTD mouse model. J Mol 
Neurosci [Internet]. 2011 Nov;45(3):432–7. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/21822709 
105.  Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, et al. Tau-
induced defects in synaptic plasticity, learning, and memory are reversible in transgenic 
mice after switching off the toxic Tau mutant. J Neurosci [Internet]. 2011 Feb 
16;31(7):2511–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21325519 
106.  Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. A beta peptide 
immunization reduces behavioural impairment and plaques in a model of Alzheimer’s 
disease. Nature [Internet]. 408(6815):979–82. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/11140685 
107.  Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with 
amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 
[Internet]. 1999 Jul 8;400(6740):173–7. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/10408445 
108.  Bittar A, Sengupta U, Kayed R. Prospects for strain-specific immunotherapy in 
Alzheimer’s disease and tauopathies. NPJ vaccines [Internet]. 2018;3:9. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/29507776 
Cognition Therapeutics, Inc.  May 2019 
31 
CONFIDENTIAL 
109.  Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA 
Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s 
Dement [Internet]. Elsevier Inc.; 2018;14(4):535–62. Available from: 
https://doi.org/10.1016/j.jalz.2018.02.018 
110.  McCleery J, Flicker L, Richard E, Quinn TJ. When is Alzheimer’s not dementia-Cochrane 
commentary on The National Institute on Ageing and Alzheimer’s Association Research 
Framework for Alzheimer’s Disease. Age Ageing [Internet]. 2019;48(2):174–7. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/30329009 
111.  Finnema SJ, Nabulsi NB, Eid T, Detyniecki K, Lin S, Chen M, et al. Imaging synaptic 
density in the living human brain. Sci Transl Med [Internet]. 2016 Jul 20;8(348):348ra96. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/27440727 
112.  Constantinescu CC, Tresse C, Zheng M, Gouasmat A, Carroll VM, Mistico L, et al. 
Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle 
Protein 2A (SV2A) PET Tracers. Mol Imaging Biol [Internet]. 2019 Jun 6;21(3):509–18. 
Available from: http://link.springer.com/10.1007/s11307-018-1260-5 
113.  Li S, Cai Z, Wu X, Holden D, Pracitto R, Kapinos M, et al. Synthesis and in Vivo 
Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A 
(SV2A) in Nonhuman Primates. ACS Chem Neurosci [Internet]. 2019 Mar 
20;10(3):1544–54. Available from: 
https://pubs.acs.org/doi/10.1021/acschemneuro.8b00526 
114.  Chen M-K, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin S, et al. Assessing 
Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron 




115.  Davidsson P, Jahn R, Bergquist J, Ekman R, Blennow K. Synaptotagmin, a synaptic 
vesicle protein, is present in human cerebrospinal fluid: a new biochemical marker for 
synaptic pathology in Alzheimer disease? Mol Chem Neuropathol [Internet]. 1996 
Cognition Therapeutics, Inc.  May 2019 
32 
CONFIDENTIAL 
Feb;27(2):195–210. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8962603 
116.  Davidsson P, Puchades M, Blennow K. Identification of synaptic vesicle, pre- and 
postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing. 
Electrophoresis [Internet]. 1999 Mar;20(3):431–7. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/10217148 
117.  Kvartsberg H, Lashley T, Murray CE, Brinkmalm G, Cullen NC, Höglund K, et al. The 
intact postsynaptic protein neurogranin is reduced in brain tissue from patients with 
familial and sporadic Alzheimer’s disease. Acta Neuropathol [Internet]. 2019;137(1):89–
102. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30244311 
118.  Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, et al. 
Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer’s 
disease. Brain Res [Internet]. Elsevier B.V.; 2010;1362:13–22. Available from: 
http://dx.doi.org/10.1016/j.brainres.2010.09.073 
119.  Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Öhrfelt A, Andersson K, et al. 
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive 
decline in prodromal Alzheimer’s disease. Alzheimers Dement [Internet]. 2015 
Oct;11(10):1180–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25533203 
120.  Portelius E, Zetterberg H, Skillbäck T, Törnqvist U, Andreasson U, Trojanowski JQ, et al. 
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in 
Alzheimer’s disease. Brain [Internet]. 2015 Nov;138(Pt 11):3373–85. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/26373605 
121.  Tarawneh R, D’Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, et al. Diagnostic 
and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. JAMA 
Neurol [Internet]. 2016;73(5):561–71. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/27018940 
122.  Portelius E, Olsson B, Höglund K, Cullen NC, Kvartsberg H, Andreasson U, et al. 
Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical 
phenotypes and neuropathology. Acta Neuropathol [Internet]. 2018;136(3):363–76. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/29700597 
Cognition Therapeutics, Inc.  May 2019 
33 
CONFIDENTIAL 
123.  Wellington H, Paterson RW, Portelius E, Törnqvist U, Magdalinou N, Fox NC, et al. 
Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 
2016;86(9):829–35.  
124.  Sandelius Å, Portelius E, Källén Å, Zetterberg H, Rot U, Olsson B, et al. Elevated CSF 
GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology. 
Alzheimers Dement [Internet]. 2019;15(1):55–64. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/30321501 
125.  Brinkmalm A, Brinkmalm G, Honer WG, Frölich L, Hausner L, Minthon L, et al. SNAP-
25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in 
Alzheimer’s disease. Mol Neurodegener [Internet]. 2014;9:53. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4253625&tool=pmcentrez&re
ndertype=abstract 
126.  Rauchmann B-S, Sadlon A, Perneczky R, Alzheimer’s Disease Neuroimaging Initiative. 
Soluble TREM2 and Inflammatory Proteins in Alzheimer’s Disease Cerebrospinal Fluid. J 
Alzheimers Dis [Internet]. 2020 Jan 13; Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/31958095 
127.  Suárez-Calvet M, Kleinberger G, Araque Caballero MÁ, Brendel M, Rominger A, 
Alcolea D, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for 
microglia activity in early-stage Alzheimer’s disease and associate with neuronal injury 
markers. EMBO Mol Med [Internet]. 2016;8(5):466–76. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/26941262 
128.  Piccio L, Deming Y, Del-Águila JL, Ghezzi L, Holtzman DM, Fagan AM, et al. 
Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with 
mutation status. Acta Neuropathol [Internet]. 2016;131(6):925–33. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/26754641 
129.  Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, et al. 
Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease. Mol 
Neurodegener [Internet]. 2016 Jan 12;11:3. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/26754172 
Cognition Therapeutics, Inc.  May 2019 
34 
CONFIDENTIAL 
130.  Lashley T, Schott JM, Weston P, Murray CE, Wellington H, Keshavan A, et al. Molecular 
biomarkers of Alzheimer’s disease: progress and prospects. Dis Model Mech [Internet]. 
2018 May 8;11(5). Available from: http://www.ncbi.nlm.nih.gov/pubmed/29739861 
131.  Lleó A, Núñez-Llaves R, Alcolea D, Chiva C, Balateu-Paños D, Colom-Cadena M, et al. 
Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical 
Alzheimer’s Disease Cerebrospinal Fluid. Mol Cell Proteomics [Internet]. 2019 
Mar;18(3):546–60. Available from: 
http://www.mcponline.org/lookup/doi/10.1074/mcp.RA118.001290 
132.  Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, et al. Cerebrospinal 
fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s 
disease. EMBO Mol Med [Internet]. 2019 Dec 11;11(12). Available from: 
https://onlinelibrary.wiley.com/doi/abs/10.15252/emmm.201911170 
133.  Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM, Galasko D, et al. 
Prediction of conversion from mild cognitive impairment to dementia with neuronally 
derived blood exosome protein profile. Alzheimer’s Dement (Amsterdam, Netherlands) 
[Internet]. 2016;3:63–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27408937 
134.  Poil SS, de Haan W, van der Flier WM, Mansvelder HD, Scheltens P, Linkenkaer-Hansen 
K. Integrative EEG biomarkers predict progression to Alzheimer’s disease at the MCI 
stage. Front Aging Neurosci. 2013;5(OCT):1–12.  
135.  van der Zande JJ, Gouw AA, Steenoven I van, Scheltens P, Stam CJ, Lemstra AW. EEG 
characteristics of dementia with Lewy Bodies, Alzheimer’s Disease and mixed pathology. 
Front Aging Neurosci. 2018;10(JUL):1–10.  
136.  Schomer DL, da Silva FL, editors. Niedermeyer’s electroencephalography. Basic 
principles, clinical applications, and related fields. Sixth Edit. Philadelphia, PA: 
Lippincott Wiliams & Wilkins; 2010.  
137.  Ebersole JS, Pedley TA. Current practice of clinical electroencephalography, 3rd edn. Eur 
J Neurol [Internet]. 2003 Sep;10(5):604–5. Available from: 
http://doi.wiley.com/10.1046/j.1468-1331.2003.00643.x 
138.  Jeong J. EEG dynamics in patients with Alzheimer’s disease. Clin Neurophysiol 
Cognition Therapeutics, Inc.  May 2019 
35 
CONFIDENTIAL 
[Internet]. 2004 Jul;115(7):1490–505. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/15203050 
139.  Smailovic U, Koenig T, Laukka EJ, Kalpouzos G, Andersson T, Winblad B, et al. EEG 
time signature in Alzheimer´s disease: Functional brain networks falling apart. 
NeuroImage Clin [Internet]. Elsevier; 2019;24(October):102046. Available from: 
https://doi.org/10.1016/j.nicl.2019.102046 
140.  Smailovic U, Koenig T, Kåreholt I, Andersson T, Kramberger MG, Winblad B, et al. 
Quantitative EEG power and synchronization correlate with Alzheimer’s disease CSF 
biomarkers. Neurobiol Aging [Internet]. Elsevier Inc; 2018;63:88–95. Available from: 
https://doi.org/10.1016/j.neurobiolaging.2017.11.005 
141.  Gouw AA, Alsema AM, Tijms BM, Borta A, Scheltens P, Stam CJ, et al. EEG spectral 
analysis as a putative early prognostic biomarker in nondemented, amyloid positive 
subjects. Neurobiol Aging [Internet]. Elsevier Inc; 2017;57:133–42. Available from: 
http://linkinghub.elsevier.com/retrieve/pii/S0197458017301847 
142.  Gianotti LRR, Künig G, Faber PL, Lehmann D, Pascual-Marqui RD, Kochi K, et al. 
Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging 
in Alzheimer’s disease. Psychopharmacology (Berl) [Internet]. 2008 Jun;198(3):323–32. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/18446328 
143.  Adler G, Brassen S. Short-term rivastigmine treatment reduces EEG slow-wave power in 
Alzheimer patients. Neuropsychobiology. 2001 Jan;43(4):273–6.  
144.  Adler G, Brassen S, Chwalek K, Dieter B, Teufel M. Prediction of treatment response to 
rivastigmine in Alzheimer’s dementia. J Neurol Neurosurg Psychiatry. 2004;75:292–4.  
145.  Moretti D V, Frisoni GB, Binetti G, Zanetti O. Comparison of the effects of transdermal 
and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s 
disease. Front Aging Neurosci. 2014 Jan;6(July):179.  
146.  Brassen S, Adler G. Short-term effects of acetylcholinesterase inhibitor treatment on EEG 
and memory performance in Alzheimer patients: an open, controlled trial. 
Pharmacopsychiatry [Internet]. 2003 Nov;36(6):304–8. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/14663655 
Cognition Therapeutics, Inc.  May 2019 
36 
CONFIDENTIAL 
147.  Babiloni C, Del Percio C, Bordet R, Bourriez J-L, Bentivoglio M, Payoux P, et al. Effects 
of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic 
rhythms in Alzheimer’s disease patients. Clin Neurophysiol [Internet]. International 
Federation of Clinical Neurophysiology; 2013 May;124(5):837–50. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/23098644 
148.  Scheltens P, Twisk JWR, Blesa R, Scarpini E, von Arnim CAF, Bongers A, et al. Efficacy 
of Souvenaid in mild Alzheimer’s disease: results from a randomized, controlled trial. J 
Alzheimers Dis. 2012 Jan;31(1):225–36.  
149.  Scheltens P, Hallikainen M, Grimmer T, Duning T, Alida G, Teunissen C, et al. Safety, 
tolerability and efficacy of the glutaminyl-cyclase inhibitor PQ912 in Alzheimer’s disease: 
results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimers Res 
Ther. 2018;  
150.  van Straaten EC, Scheltens P, Gouw A a, Stam CJ. Eyes-closed task-free 
electroencephalography in clinical trials for Alzheimer’s disease: an emerging method 
based upon brain dynamics. Alzheimers Res Ther. 2014 Jan;6(9):86.  
151.  de Waal H, Stam CJJ, Lansbergen MMM, Wieggers RLL, Kamphuis PJGHJGH, 
Scheltens P, et al. The effect of souvenaid on functional brain network organisation in 
patients with mild Alzheimer’s disease: a randomised controlled study. PLoS One 
[Internet]. 2014 Jan;9(1):e86558. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/24475144 
152.  Attwell D, Iadecola C. The neural basis of functional brain imaging signals. Trends 
Neurosci [Internet]. 2002 Dec;25(12):621–5. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/12446129 
153.  Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in 
preclinical Alzheimer’s disease. Ann N Y Acad Sci [Internet]. 2008 Dec;1147:180–95. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/19076441 
154.  Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. 
Associations between cognitive, functional, and FDG-PET measures of decline in AD and 
MCI. Neurobiol Aging [Internet]. 2011 Jul;32(7):1207–18. Available from: 




155.  Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer’s 
Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 
[Internet]. 2010 May;6(3):221–9. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/20451870 
156.  Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward 
defining the preclinical stages of Alzheimer’s disease: recommendations from the 
National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines 
for Alzheimer’s disease. Alzheimers Dement [Internet]. 2011 May;7(3):280–92. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/21514248 
157.  van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, et al. Effect 
of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized 
Clinical Trial. JAMA Neurol [Internet]. 2019 Jul 22; Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/31329216 
158.  HARRISON, J.E. MARUFF, P. SCHEMBRI, A., NOVAK, P., ONDRUS, M., PRENN-
GOLOGRANC, C., KATINA S. Stability, reliability, validity and relationship to 
biomarkers of the BRADER – a new assessment for capturing cognitive changes in 
patients with Alzheimer’s disease. Alzheimer’s Res Ther.  
159.  Harrison JE. Cognition comes of age: comments on the new FDA draft guidance for early 
Alzheimer’s disease. Alzheimers Res Ther [Internet]. 2018;10(1):61. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/29958538 
 
